priors.science/reviews/systemic-sclerosis-treatment

Systemic Sclerosis Treatment

The current evidence on 20 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

20claims tracked
134primary papers reviewed
6 Jul 2026latest evidence review
Weeklyre-scored against new papers
0 Established · 16 Likely · 4 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableNintedanib slows forced vital capacity decline in systemic sclerosis-associated interstitial lung diseaseCluster 1Likely83%15
StableMycophenolate mofetil versus cyclophosphamide in systemic sclerosis-associated interstitial lung diseaseCluster 2Likely80%13
StableCyclophosphamide improves forced vital capacity in systemic sclerosis-associated interstitial lung diseaseCluster 2Likely79%9
StableHaematopoietic stem cell transplantation gives superior survival versus cyclophosphamide in diffuse cutaneous systemic sclerosisCluster 6Likely79%6
StableBosentan reduces digital ulcers in systemic sclerosisCluster 7Likely78%6
StableMycophenolate mofetil has superior tolerability versus cyclophosphamide in systemic sclerosisCluster 2Likely77%10
StableEndothelin receptor antagonists and phosphodiesterase-5 inhibitors in systemic sclerosis-associated pulmonary arterial hypertension survivalCluster 5Likely75%4
StableNintedanib effect consistent with mycophenolate mofetilCluster 1Likely74%10
StableRituximab stabilizes forced vital capacity in systemic sclerosis-associated interstitial lung diseaseCluster 4Likely74%6
StableIloprost reduces digital ulcers in systemic sclerosisCluster 7Likely73%6
StableAngiotensin-converting enzyme inhibitors improve outcomes in scleroderma renal crisisCluster 8Likely73%6
StableMacitentan reduces worsening in systemic sclerosis-associated pulmonary arterial hypertensionCluster 5Likely72%4
StableSelexipag reduces pulmonary arterial hypertension morbidityCluster 5Likely72%3
StableRituximab reduces skin score in diffuse cutaneous systemic sclerosisCluster 4Likely71%6
StableTocilizumab preserves forced vital capacity in systemic sclerosis-associated interstitial lung diseaseCluster 3Likely67%6
StableTocilizumab reduces skin score in diffuse cutaneous systemic sclerosisCluster 3Uncertain60%6
StablePrior angiotensin-converting enzyme inhibitor use worsens scleroderma renal crisis outcomesCluster 8Uncertain56%6
StableAbatacept reduces skin score in diffuse cutaneous systemic sclerosisCluster 9Uncertain55%4
StableBaricitinib reduces inflammation in systemic sclerosisCluster 9Uncertain49%2
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic